|
Market Closed -
Nasdaq
16:00:00 2026-11-04 EST
|
5-day change | 1st Jan Change | ||
| 28.02 USD | +3.32% |
|
+9.58% | +4.63% |
| 08-18 | Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating | MT |
| 08-07 | Amphastar Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026 |
Company Valuation: Amphastar Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,114 | 1,354 | 2,963 | 1,785 | 1,231 | 1,192 | - | - |
| Change | - | 21.52% | 118.8% | -39.75% | -31.07% | -3.14% | - | - |
| Enterprise Value (EV) 1 | 1,114 | 1,354 | 2,963 | 2,235 | 1,669 | 1,498 | 1,382 | 1,258 |
| Change | - | 21.52% | 118.8% | -24.56% | -25.34% | -10.25% | -7.76% | -8.93% |
| P/E | 18.6x | 16.1x | 23.8x | 12.1x | 13.2x | 12.9x | 10.6x | 11.3x |
| PBR | - | - | - | 2.41x | 1.55x | 1.35x | - | - |
| PEG | - | 0.4x | 0.5x | 0.7x | -0.4x | 1.87x | 0.5x | -1.86x |
| Capitalization / Revenue | 2.55x | 2.71x | 4.6x | 2.44x | 1.71x | 1.59x | 1.52x | 1.48x |
| EV / Revenue | 2.55x | 2.71x | 4.6x | 3.05x | 2.32x | 2x | 1.76x | 1.56x |
| EV / EBITDA | 11.2x | 9.21x | 10.4x | 7.18x | 6.74x | 7.04x | 6.51x | 6.06x |
| EV / EBIT | 14.5x | 11.1x | 12.1x | 8.66x | 7.73x | 8.32x | 7.52x | 6.5x |
| EV / FCF | - | 20.8x | - | 13x | 13.8x | 11.2x | 11.9x | 10.2x |
| FCF Yield | - | 4.81% | - | 7.71% | 7.26% | 8.95% | 8.4% | 9.77% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.25 | 1.74 | 2.6 | 3.06 | 2.03 | 2.17 | 2.64 | 2.48 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 437.8 | 499 | 644.4 | 732 | 719.9 | 747.3 | 784 | 807.7 |
| EBITDA 1 | 99.1 | 147.1 | 283.9 | 311.1 | 247.5 | 212.9 | 212.1 | 207.8 |
| EBIT 1 | 76.9 | 121.8 | 245.8 | 258.2 | 215.9 | 180.1 | 183.7 | 193.5 |
| Net income 1 | 62.12 | 91.39 | 137.5 | 159.5 | 98.09 | 99.32 | 115.4 | 111.1 |
| Net Debt 1 | - | - | - | 450 | 438.3 | 306 | 189.8 | 66.41 |
| Reference price 2 | 23.29 | 28.02 | 61.85 | 37.13 | 26.78 | 28.02 | 28.02 | 28.02 |
| Nbr of stocks (in thousands) | 47,849 | 48,331 | 47,907 | 48,081 | 45,952 | 42,538 | - | - |
| Announcement Date | 3/10/22 | 2/28/23 | 2/28/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 12.5x | 1.95x | 6.86x | -.--% | 1.15B | |
| 41.24x | 13.94x | 30.97x | 0.48% | 1,255B | |
| 38.96x | 6.55x | 18.42x | 2.01% | 641B | |
| 36.79x | 8.37x | 17.26x | 2.42% | 505B | |
| 21.08x | 5.12x | 12.75x | 2.56% | 381B | |
| 95.75x | 5.88x | 25.02x | 2.35% | 357B | |
| 22.88x | 5.88x | 14.19x | 2.73% | 303B | |
| 24.26x | 4.85x | 13.68x | 1.8% | 286B | |
| 29.25x | 7.46x | 13.36x | 2.19% | 249B | |
| -40.09x | 7.32x | 45.96x | 1.97% | 208B | |
| Average | 28.26x | 6.73x | 19.85x | 1.85% | 418.64B | |
| Weighted average by Cap. | 35.92x | 8.72x | 22.52x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMPH Stock
- Valuation Amphastar Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
